Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Summary

OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these patients.

Timeline

Start

2000-12

Primary completion

2007-08

Completion

—

Drugs

Indications